Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1210 with Chemotherapy or Apatinib for ESCC
NCT03917966Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2020
- Primary completion
- Oct 2023
- Countries
- 1
01
Overview
Phase 2, open-label trial of camrelizumab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT03917966.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917966.